Market Closed -
Australian S.E.
11:40:47 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.023
AUD
|
0.00%
|
|
-14.81%
|
-4.17%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
37.68
|
24.09
|
13.94
|
30.65
|
16.97
|
8.8
|
Enterprise Value (EV)
1 |
35.38
|
18.54
|
12.76
|
26.54
|
12.31
|
8.025
|
P/E ratio
|
-9.72
x
|
-3.2
x
|
-2.32
x
|
-5.2
x
|
-2.48
x
|
-1.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
18.7
x
|
6.81
x
|
3.64
x
|
7.69
x
|
6.16
x
|
2.54
x
|
EV / Revenue
|
17.5
x
|
5.24
x
|
3.33
x
|
6.66
x
|
4.47
x
|
2.31
x
|
EV / EBITDA
|
-9.17
x
|
-3.11
x
|
-2.2
x
|
-4.93
x
|
-2.06
x
|
-1.66
x
|
EV / FCF
|
-14.2
x
|
-4.86
x
|
-3.5
x
|
-9.6
x
|
-6.14
x
|
-2.46
x
|
FCF Yield
|
-7.04%
|
-20.6%
|
-28.6%
|
-10.4%
|
-16.3%
|
-40.6%
|
Price to Book
|
9.25
x
|
3.22
x
|
3.76
x
|
4.8
x
|
3.15
x
|
4.61
x
|
Nbr of stocks (in thousands)
|
1,01,846
|
1,50,569
|
1,63,946
|
2,45,176
|
3,14,185
|
3,66,680
|
Reference price
2 |
0.3700
|
0.1600
|
0.0850
|
0.1250
|
0.0540
|
0.0240
|
Announcement Date
|
06/09/18
|
29/08/19
|
27/08/20
|
27/08/21
|
28/08/22
|
25/08/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.02
|
3.539
|
3.828
|
3.984
|
2.754
|
3.469
|
EBITDA
1 |
-3.859
|
-5.957
|
-5.798
|
-5.389
|
-5.966
|
-4.841
|
EBIT
1 |
-3.862
|
-5.989
|
-5.84
|
-5.418
|
-5.999
|
-4.871
|
Operating Margin
|
-191.17%
|
-169.24%
|
-152.57%
|
-135.99%
|
-217.85%
|
-140.42%
|
Earnings before Tax (EBT)
1 |
-3.855
|
-5.918
|
-6.006
|
-5.628
|
-6.061
|
-4.851
|
Net income
1 |
-3.855
|
-5.918
|
-6.006
|
-5.628
|
-6.061
|
-4.851
|
Net margin
|
-190.82%
|
-167.24%
|
-156.92%
|
-141.26%
|
-220.11%
|
-139.84%
|
EPS
2 |
-0.0381
|
-0.0500
|
-0.0366
|
-0.0240
|
-0.0218
|
-0.0152
|
Free Cash Flow
1 |
-2.491
|
-3.811
|
-3.647
|
-2.764
|
-2.005
|
-3.258
|
FCF margin
|
-123.29%
|
-107.7%
|
-95.29%
|
-69.37%
|
-72.82%
|
-93.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/09/18
|
29/08/19
|
27/08/20
|
27/08/21
|
28/08/22
|
25/08/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2.31
|
5.56
|
1.18
|
4.1
|
4.66
|
0.78
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.49
|
-3.81
|
-3.65
|
-2.76
|
-2.01
|
-3.26
|
ROE (net income / shareholders' equity)
|
-65.2%
|
-102%
|
-107%
|
-112%
|
-103%
|
-133%
|
ROA (Net income/ Total Assets)
|
-38.5%
|
-54.5%
|
-45%
|
-42.4%
|
-38.1%
|
-33.1%
|
Assets
1 |
10
|
10.87
|
13.34
|
13.26
|
15.92
|
14.64
|
Book Value Per Share
2 |
0.0400
|
0.0500
|
0.0200
|
0.0300
|
0.0200
|
0.0100
|
Cash Flow per Share
2 |
0.0200
|
0.0400
|
0.0200
|
0.0200
|
0.0300
|
0.0100
|
Capex
1 |
0
|
0.17
|
0
|
0
|
0.03
|
0
|
Capex / Sales
|
0.16%
|
4.82%
|
0.06%
|
0.05%
|
0.92%
|
0.06%
|
Announcement Date
|
06/09/18
|
29/08/19
|
27/08/20
|
27/08/21
|
28/08/22
|
25/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -4.17% | 8.09M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|